处于研发阶段的抗HIV新药综述
New Drugs in the Pipeline for the Treatment of HIV: a Review.
作者信息
Gravatt Leigh Anne Hylton, Leibrand Crystal R, Patel Sulay, McRae MaryPeace
机构信息
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, VCU School of Pharmacy, 410 North 12th Street, PO Box 980533, Richmond, VA, 23298-0533, USA.
出版信息
Curr Infect Dis Rep. 2017 Sep 19;19(11):42. doi: 10.1007/s11908-017-0601-x.
PURPOSE OF REVIEW
The purpose of this paper is to review therapies with new mechanisms of action for the treatment of HIV that are at least in phase 2 clinical trials.
RECENT FINDINGS
There are several new mechanisms of action being represented within clinical development, including histone deacetylase (HDAC) inhibitors, gene therapies, broadly neutralizing anti-HIV antibodies, immune modulation, and drugs with new mechanisms to block HIV entry. The new therapies are being developed for both as add-on therapy to existing combination antiretroviral therapy and as agents to be used during treatment interruption. The current drugs in development have had varying degrees of success in the early trials. Each of these new drugs may potentially fill a void in current antiretroviral therapy (ART) therapies, which will ultimately lead to improved outcomes in HIV-infected individuals.
综述目的
本文旨在综述至少处于2期临床试验阶段的、具有新作用机制的抗HIV治疗方法。
最新发现
临床开发中有几种新的作用机制，包括组蛋白脱乙酰酶（HDAC）抑制剂、基因疗法、广泛中和抗HIV抗体、免疫调节以及具有阻止HIV进入新机制的药物。这些新疗法既作为现有联合抗逆转录病毒疗法的附加疗法进行开发，也作为治疗中断期间使用的药物进行开发。目前正在研发的药物在早期试验中取得了不同程度的成功。这些新药中的每一种都有可能填补当前抗逆转录病毒疗法（ART）的空白，最终改善HIV感染者的治疗效果。
Zotero 插件